EGFR-Mutated Lung Cancer Video Perspectives
Erminia Massarelli, MD, PhD, MS
Massarelli reports receiving honoraria from AstraZeneca and Merck; consulting and/or advising Bristol Myers Squibb Foundation, Genentech/Roche, Janssen Scientific Affairs, Merck, and Sanofi; serving on a speakers' bureau for AstraZeneca; receiving research funding from AstraZeneca, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Merck, Pfizer, and Tessa Therapeutics; and receiving travel, accommodations, and expenses from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Merck, and Pfizer.
VIDEO: Expert highlights EGFR-mutated lung cancer treatment pipeline
Transcript
Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
A very important trial is currently ongoing, the understanding if concurrent treatment with chemotherapy, endo therapy, is an important step, and this is ongoing. We don't have results yet for that. And this includes also the following, basically the disappearance of B G mutation from the bloodstream you know, in the, with liquid biopsies. And if they still have the presence of the E GCA mutation after starting treatment they randomized to either having chemotherapy or not. This is one, I think important question that will be answered. The second important question is when you do upon progression molecular test.
I think the best is within a clinical trial because then you're gonna have options. They're available to patients to molecular test results. As of, you know, like standard treatments that are targeted to specific mechanisms of resistance. One is, as I mentioned, read the other one graphed.
We have also have part two, targeted treatments. But we do not have really standard treatment that will allow us, you know, to really use two molecular targeted therapists together yet. So, I think the best would be to they patients into clinical trials.
There are many phase one and two clinical trials and also phase treatment. And they're going, you know, other than chemotherapy and other important mechanism, you know resistance is through P three kinase pathway. And at the moment we don't have any approved targeted therapy that could potentially target these escape mechanisms. We are gonna have several trials, hopefully, you know some analysis will be available as early as 2022.
